Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 1;29(1):92–99. doi: 10.1158/1078-0432.CCR-21-3577

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 2. Kaplan–Meier plot of OS in cohort A ctDNA subgroup* (A), and cohort A ITT population (B)†. *Patients with BRCA/ATM alterations identified by ctDNA testing; †Patients with BRCA/ATM alterations identified by tissue testing. BRCA/ATM; BRCA1, BRCA2, or ATM; ctDNA, circulating tumor DNA; ITT, intention-to-treat; OS, overall survival. Figure 2B from N Engl J Med, Hussain M, et al., Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer, Vol. 383, pp. 2345–57, Copyright 2020 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. — Kaplan–Meier plot of OS in Cohort A ctDNA subgroup* (A), and Cohort A ITT population (B)^†. *Patients with BRCA/ATM alterations identified by ctDNA testing; ^†Patients with BRCA/ATM alterations identified by tissue testing. (Figure 2B from N Engl J Med, Hussain M, et al., Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer, Vol. 383, pp. 2345–57, Copyright 2020 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.)